1-13 of 13
Laura Sun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

Laura Sun, Kathryn T. Maples, Kevin H. Hall, Yuan Liu, Yichun Cao, Nisha S. Joseph, Craig C Hofmeister, Jonathan L. Kaufman, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, R Donald Harvey
Journal: Blood
Blood (2022) 140 (Supplement 1): 7131–7132.
https://doi.org/10.1182/blood-2022-159189
Published: 2022
Journal Articles

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Sumit Madan, Al-Ola Abdallah, Andrew J. Cowan, William I. Bensinger, Jens Hillengass, Xavier Leleu, Eva Medvedova, Caitlin Costello, Brea Lipe, Henning Schade, Rajneesh Nath, Liping Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2021-148176
Published: 2021
Journal Articles

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1185.
https://doi.org/10.1182/blood-2021-151880
Published: 2021
Journal Articles

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD, Lisa Knapp, Bryan Lemon, PhD, Liping Laura Sun, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-136012
Published: 2020
Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1285.
https://doi.org/10.1182/blood-2019-123961
Published: 2019
Journal Articles

Preclinical Characterization of Combinability and Potential Synergy of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody with Chemotherapy and PD-1/PD-L1 Blockade

Liping Laura Sun, PhD, Peiyin Wang, Robyn Clark, Maria Hristopoulos, Diego Ellerman, PhD, Mary Mathieu, Yu-Waye Chu, Hong Wang, PhD, Klara Totpal, PhD, Allen J. Ebens, PhD, Andrew G. Polson, PhD, Stephen Gould, PhD
Journal: Blood
Blood (2016) 128 (22): 4168.
https://doi.org/10.1182/blood.V128.22.4168.4168
Published: 2016
Journal Articles

Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies

L. Laura Sun, PhD, Xiaocheng Chen, Yvonne Chen, Mark S. Dennis, Diego Ellerman, PhD, Clarissa Johnson, Mary Mathieu, Amy Oldendorp, Andrew G. Polson, PhD, Arthur Reyes, Eric Stefanich, Hong Wang, PhD, Peiyin Wang, Bing Zheng, Allen J. Ebens, PhD
Journal: Blood
Blood (2014) 124 (21): 4507.
https://doi.org/10.1182/blood.V124.21.4507.4507
Published: 2014
Journal Articles

Application of a new wall-less plate technology to complex multistep cell-based investigations using suspension cells

e-blood
Gabriel A. Quiñones, Travis I. Moore, Katrina Nicholes, Hyunjae Lee, Sudong Kim, Laura Sun, Noo Li Jeon, Jean-Philippe Stephan
Journal: Blood
Blood (2013) 121 (7): e25–e33.
https://doi.org/10.1182/blood-2012-07-446294
Published: 2013
Includes: Multimedia, Supplemental data
Journal Articles

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies

Veerendra Munugalavadla, PhD, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby, Karen Fitzgerald, Lori S. Friedman, Stephen E. Gould, Jane R. Kenny, Heather Maecker, John Moffat, Marina Moskalenko, Patricia Pacheco, Alham Saadat, Dion Slaga, Laura Sun, Gina Wang, Yagai Yang, Allen J. Ebens, PhD
Journal: Blood
Blood (2010) 116 (21): 4084.
https://doi.org/10.1182/blood.V116.21.4084.4084
Published: 2010
Journal Articles

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity

Allen J. Ebens, PhD, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby, Karen Fitzgerald, Lori S. Friedman, Stephen E. Gould, Jane R. Kenny, Heather Maecker, John Moffat, Marina Moskalenko, Patricia Pacheco, Alham Saadat, Dion Slaga, Laura Sun, Gina Wang, Yagai Yang, Veerendra Munugalavadla, PhD
Journal: Blood
Blood (2010) 116 (21): 3001.
https://doi.org/10.1182/blood.V116.21.3001.3001
Published: 2010
Journal Articles

PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.

Xiaoju Max Ma, PhD, Changchun Du, BM, BS, Laura Sun, Xiaoyan Shi, Ph.D, Lori Friedman, David Dornan, Ph.D, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 1057.
https://doi.org/10.1182/blood.V114.22.1057.1057
Published: 2009
Journal Articles

The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells.

Laura Sun, Leanne Berry, Changchun Du, BM, BS, Xiaoju Max Ma, Lily Shi, Bruno C. Medeiros, MD, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 3787.
https://doi.org/10.1182/blood.V114.22.3787.3787
Published: 2009
Journal Articles

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

Veerendra Munugalavadla, PhD, Leanne Berry, Changchun Du, BM, BS, Sanjeev Mariathasan, Dion Slaga, Laura Sun, Marta Chesi, Peter Leif Bergsagel, MD, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 3788.
https://doi.org/10.1182/blood.V114.22.3788.3788
Published: 2009